CN115335078A - 组合用于治疗过敏疾病的FC-ε-RI-β和MS4A6A的外显子跳跃 - Google Patents

组合用于治疗过敏疾病的FC-ε-RI-β和MS4A6A的外显子跳跃 Download PDF

Info

Publication number
CN115335078A
CN115335078A CN202080092446.5A CN202080092446A CN115335078A CN 115335078 A CN115335078 A CN 115335078A CN 202080092446 A CN202080092446 A CN 202080092446A CN 115335078 A CN115335078 A CN 115335078A
Authority
CN
China
Prior art keywords
sequence
fcεriβ
ms4a6a
exon
antisense oligomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080092446.5A
Other languages
English (en)
Chinese (zh)
Inventor
G·P·克鲁斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
North Carolina State University
Original Assignee
North Carolina State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Carolina State University filed Critical North Carolina State University
Publication of CN115335078A publication Critical patent/CN115335078A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202080092446.5A 2019-11-08 2020-11-09 组合用于治疗过敏疾病的FC-ε-RI-β和MS4A6A的外显子跳跃 Pending CN115335078A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962932664P 2019-11-08 2019-11-08
US62/932,664 2019-11-08
PCT/US2020/059682 WO2021092562A1 (en) 2019-11-08 2020-11-09 Exon skipping of fc-epsilon-ri-beta and ms4a6a in combination for the treatment of allergic diseases

Publications (1)

Publication Number Publication Date
CN115335078A true CN115335078A (zh) 2022-11-11

Family

ID=75849333

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080092446.5A Pending CN115335078A (zh) 2019-11-08 2020-11-09 组合用于治疗过敏疾病的FC-ε-RI-β和MS4A6A的外显子跳跃

Country Status (6)

Country Link
US (1) US20220380777A1 (https=)
EP (1) EP4054639A4 (https=)
JP (1) JP2023501347A (https=)
CN (1) CN115335078A (https=)
AU (1) AU2020378207A1 (https=)
WO (1) WO2021092562A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112023062A (zh) * 2020-09-18 2020-12-04 北京基因安科技有限公司 一个用可溶性IgE受体抑制过敏反应的方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136435A1 (en) 2016-02-01 2017-08-10 The Usa, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer National Institute Of Health Compounds for modulating fc-epsilon-ri-beta expression and uses thereof
CN120019145A (zh) * 2022-09-28 2025-05-16 阿塔兰塔治疗公司 用于治疗神经炎性疾病的组合物和方法
CN116219009B (zh) * 2022-10-19 2024-10-01 杭州师范大学 小胶质细胞特异性表达的ms4a6a在胶质母细胞瘤治疗或预后评估试剂盒上的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101128586A (zh) * 2004-12-22 2008-02-20 健泰科生物技术公司 制备可溶性多跨膜蛋白的方法
US20080200409A1 (en) * 2004-06-28 2008-08-21 Stephen Donald Wilson Antisense Oligonucleotides For Inducing Exon Skipping and Methods of Use Thereof
US20190062756A1 (en) * 2016-02-01 2019-02-28 North Carolina State University Compounds for modulating fc-epsilon-ri-beta expression and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040137566A1 (en) * 2001-12-10 2004-07-15 Tedder Thomas F. Identification of novel ms4a gene family members expressed by hematopoietic cells
CN103074422A (zh) * 2012-12-29 2013-05-01 深圳市第三人民医院 Ms4a6a基因的用途
CN105969901B (zh) * 2016-07-27 2019-10-11 北京泱深生物信息技术有限公司 Ms4a6a作为多发性骨髓瘤诊治标志物的用途
EP3841198A4 (en) * 2018-04-13 2022-03-02 Rene Anand REAGENTS AND METHODS FOR AUTISM AND ITS COMORBIDITIES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080200409A1 (en) * 2004-06-28 2008-08-21 Stephen Donald Wilson Antisense Oligonucleotides For Inducing Exon Skipping and Methods of Use Thereof
CN101128586A (zh) * 2004-12-22 2008-02-20 健泰科生物技术公司 制备可溶性多跨膜蛋白的方法
US20190062756A1 (en) * 2016-02-01 2019-02-28 North Carolina State University Compounds for modulating fc-epsilon-ri-beta expression and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GLENN CRUSE等: "Exon skipping of FceRlbeta eliminates expression of the high-affinity IgE receptor in mast cells with therapeutic potential for allergy", 《PNAS》, vol. 113, no. 49, pages 14115 - 14120, XP055823249, DOI: 10.1073/pnas.1608520113 *
YINGHUA LIANG等: "Structural organization of the human MS4A gene cluster on Chromosome 11q12", 《IMMUNOGENETICS》, vol. 53, pages 357 - 368 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112023062A (zh) * 2020-09-18 2020-12-04 北京基因安科技有限公司 一个用可溶性IgE受体抑制过敏反应的方法

Also Published As

Publication number Publication date
JP2023501347A (ja) 2023-01-18
EP4054639A1 (en) 2022-09-14
EP4054639A4 (en) 2025-04-30
AU2020378207A1 (en) 2022-06-23
WO2021092562A1 (en) 2021-05-14
US20220380777A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
AU2020202852B2 (en) Di-amino acid repeat-containing proteins associated with ALS
KR102606174B1 (ko) 트리플 가이드 서열을 지닌 crispr/cas9를 사용한 엑손 스키핑 변형을 위한 최적화된 전략
KR102482890B1 (ko) 아포지질단백질 (a) 발현을 조절하는 조성물 및 방법
KR102185465B1 (ko) 부계 ube3a 발현을 유도하기 위한 올리고뉴클레오티드
DK2458006T3 (en) Compounds and Methods for Modulating ApoB Expression.
CN101142321B (zh) 治疗眼病的方法和组合物
KR102365486B1 (ko) 프리칼리크레인 (pkk) 발현의 조절
ES2646716T3 (es) Oligonucleótidos antisentido para el tratamiento de amaurosis congénita de Leber
KR102149571B1 (ko) 성장 호르몬 수용체 발현을 조절하기 위한 조성물 및 방법
KR20210138587A (ko) 개선된 면역요법을 위한 조합 유전자 표적
CN115335078A (zh) 组合用于治疗过敏疾病的FC-ε-RI-β和MS4A6A的外显子跳跃
CA3040194A1 (en) Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signature
KR102236784B1 (ko) 성장 호르몬 수용체의 조절인자
KR20230034198A (ko) 종양 침윤 림프구의 활성화 및 확장 방법
CN108359668A (zh) 用于调节载脂蛋白(a)表达的方法和组合物
KR20200079304A (ko) Snca 발현을 감소시키기 위한 화합물 및 방법
KR20220113743A (ko) 병태 및 질환의 치료를 위한 안티센스 올리고머
DK2809400T3 (en) COMBINATION THERAPY INCLUDING A GROWTH HORMON VARIANT AND AN OIGONUCLEOTIDE BINDING TO THE GROWTH HORMON RECEPTOR
CN112771162B (zh) 用剪接转换寡核苷酸靶向kit诱导肥大细胞凋亡
TW202227102A (zh) 治療脂肪肝病之方法
KR20230095056A (ko) Scn2a에서 기능-상실 돌연변이와 연관된 장애를 치료하기 위한 조성물 및 방법
KR20230005933A (ko) Atxn1을 조정하는 화합물 및 방법
CN113473850A (zh) 具有遗传修饰的钠通道的啮齿动物及其使用方法
JP2025503098A (ja) ＭｕＳＫ標的化オリゴヌクレオチド
EA048246B1 (ru) Способ лечения жировой болезни печени

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination